Omri Amirav-Drory
SlowingNamed in filings at NFXOn the current fund
- Board seats filed
- 6
all filings on record
Named in filings at NFXOn the current fund
all filings on record
last 24 months
from a verified or cited source
| ImmuneBridge | Not yet classified | March 2025 | None on file |
| Talus Bioscience | Not yet classified | July 2024 | None on file |
| TwoStep Therapeutics | Not yet classified | March 2024 | None on file |
| resistanceBio | Not yet classified | January 2024 | None on file |
| La Jolla Labs | Not yet classified | October 2021 | None on file |
| Pepper Bio | Not yet classified | February 2021 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Too few filings to infer a focus. 0 of 6 filed seats classified so far.